The World Health Organization has approved the emergency use of the Sinovac vaccine developed by China.
In a written statement from the WHO, it was stated that the organization’s evaluation of the Sinovac vaccine, including inspections at the facilities where it was produced, was completed.
“The WHO today approved the Sinovac-CoronaVac Covid-19 vaccine for emergency use.” In the statement, it was pointed out that countries using this vaccine and other stakeholders have been assured that the Sinovac vaccine meets international standards for its efficacy and production.
In the statement, it was pointed out that Sinovac is an inactive vaccine and can be administered very easily due to its ease of storage.
The Strategic Advisory Group of Experts (SAGE), which advises WHO on the use of Covid-19 vaccines, has also completed its research on Sinovac, adding: “Based on the available evidence, the WHO recommends that this vaccine is administered in two doses. two to four weeks apart, in adults 18 years and over. recommend its use. expression was used.
WHO has not recommended an upper age limit for the vaccine.
PREVENTS HOSPITAL ADMISSIONS BY 100 PERCENT
In the statement, in which the results of the efficacy of the Sinovac vaccine were also shared, it was noted that 51% of those vaccinated prevented symptomatic illnesses.
In the statement, it was pointed out that severe cases and hospitalizations were prevented in 100 percent of people who studied the Sinovac vaccine.
The organization first announced on December 31 that the Kovid-19 vaccine produced by the Pfizer-BioNTech company, followed by the Oxford-AstraZeneca vaccine, the vaccine produced by the vaccine maker AstraZeneca Indian Serum Institute (SII), Astra ZenecaBio (South Korea), Moderna and Janssen, which authorized the emergency use of the vaccines it was producing.
Download the NTV application, be informed of developments